Clinical Trial Update: Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cixutumumab with temsirolimus in pediatric patients with recurrent or refractory sarcomas has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Childhood Alveolar Soft Part Sarcoma
• Childhood Angiosarcoma
• Ewing Sarcoma Peripheral Primitive Neuroectodermal Tumor
• Fibrosarcoma
• Osteosarcoma
• Rhabdomyosarcoma
• Soft Tissue Sarcoma
• Synovial Sarcoma

Drugs mentioned

• Cixutumumab (Cixutumumab)
• Temsirolimus (temsirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Childhood Alveolar Soft Part Sarcoma, Childhood Angiosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2015-03-31